The HRT 'Timing Hypothesis': Evidence

The "timing hypothesis" is one of the most discussed ideas in menopause medicine. This page explains, in plain language, what the hypothesis proposes, what major guidelines and the broad body of research generally indicate, and where the evidence remains uncertain.

What the timing hypothesis proposes

The timing hypothesis is the idea that the age at which a person starts menopausal hormone therapy (HRT, often called MHT) — and how many years have passed since menopause began — meaningfully changes the balance of benefits and risks. In broad terms, it proposes that starting therapy near the onset of menopause, in a younger and generally healthy person, tends to look more favorable than starting many years later. It grew out of efforts to reconcile seemingly conflicting findings from large studies that had enrolled women of very different ages.

Why the idea emerged

For years, headlines about hormone therapy swung dramatically, often based on reinterpreting the same large trials. A key insight was that the average participant in some influential studies was well past the typical age of menopause onset. When researchers looked separately at people who started therapy earlier versus later, the patterns appeared to differ. This led experts to propose that timing — not just whether someone uses hormones — is an important variable. The hypothesis reframed older data rather than replacing it.

What guidelines generally conclude

Major menopause and gynecology organizations now broadly emphasize individualizing decisions rather than applying a single rule to everyone. The common themes in current guidance are:

• The clearest, best-supported use of hormone therapy is relief of bothersome menopausal symptoms such as hot flashes and night sweats.
• For healthy people who begin near the onset of menopause and at a younger age, guidelines generally view the benefit-risk balance as more favorable than for those who start many years later.
• Hormone therapy is not generally recommended for the sole purpose of preventing chronic disease such as heart disease, especially when started later.
• Decisions should weigh age, time since menopause, symptom burden, personal and family history, and the specific formulation and dose.

What the timing hypothesis does and does not claim

It is important to be precise. The hypothesis suggests that timing shifts the balance of benefits and risks; it does not claim that early-start therapy is free of risk, nor that it should be used broadly to prevent disease. Risks discussed in the literature — including blood clots, stroke, and, depending on type and duration, breast cancer — remain part of the conversation regardless of timing. The hypothesis refines who is most likely to benefit and when, rather than removing the need for an individualized discussion.

Where the evidence is still developing

Open questions include how different formulations and delivery routes (for example, oral versus transdermal estrogen, and the choice of progestogen) interact with timing, the optimal duration of therapy, and the long-term effects on heart and brain health when therapy begins at different ages. Because much of the timing evidence comes from reanalysis rather than purpose-built trials, researchers continue to refine these conclusions.

How to use this overview

This is educational background, not a recommendation to start, continue, or stop any treatment. Whether and when hormone therapy is appropriate depends on your symptoms, medical history, and priorities — a discussion for you and a qualified clinician. For related background, see our treatments and conditions sections, and other overviews in the studies index.